Meghan FitzGerald serves as an advisor to several firms including Goldman Sachs, TowerBrook and Wellspring Capital. She was the CEO and managing partner at Letter One’s inaugural health vehicle from December 2016 to January 2020. Prior to this, she served for nearly 20 years as an operator and strategist working for many healthcare firms, including Merck, Pfizer and Medco. She also served as the EVP of Strategy, M&A and Health Policy at Cardinal Health and a member of the executive committee.
Ms. FitzGerald is the founder of K2HealthVentures, a life science investment fund and advisor, and volunteer at TrekMedics, an international tech non-profit. Ms. FitzGerald currently serves as a director of Roivant Sciences Ltd. She obtained a DrPH at New York Medical College, focusing on health policy and the social determinants of health, a Master of Public Health from Columbia University, and a Bachelor of Nursing from Fairfield University.